EFPIA - NEWSLETTER

EFPIA Newsletter 07 December 2017

News

05 December 2017 05122017 Escher Study Identifies Hurdles to ATMP Development in Europe

First results of a study into factors associated with successful development of Advanced Therapy Medicinal Products...

07 December 2017 07122017 European health community calls on the EU and UK to prioritise patients as crunch...

The document outlines five priorities, which the group says will ‘determine the risk in Brexit’s impact on patients...

07 December 2017 07122017 EFPIA response to Expert Panel on Effective Ways of Investing in Health (EXPH) draft...

The mission of the EXPH is to elaborate evidence-based opinions on matters related to healthcare modernisation, responsiveness...

Blogs

07 December 2017 07122017 Vyndaqel (tafamidis) – An Example of Orphan incentives in Practice

With over 7000 medicines in development, new treatments will continue to change patients’ lives; slowing disease progression,...

Events

22 JAN 2018

04102017 SafeSciMET Courses on regulatory requirements and guidelines Lisbon, Portugal

A course to provide participants with a comprehensive overview of the required in vitro and in vivo nonclinical studies,...

Learn more →

26 FEB 2018

06122017 4th European Conference on Clinical Research Vienna, Austria

A EUCROF conference

Learn more →

What we are reading

Public Private Partnerships Strenghtening Innovation and Research in Europe 07 December 2017 (The European Files)

Science in Britain will thrive - whatever the outcome of Brexit 06 December 2017 (The Telegraph)

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
Communications@efpia.eu

▶